The outcome in patients with BRAF-mutated metastatic melanoma
treated with anti-programmed death receptor-1 monotherapy or
targeted therapy in the real-world setting

J 2024

The outcome in patients with BRAF-mutated metastatic melanoma treated with anti-programmed death receptor-1 monotherapy or targeted therapy in the real-world setting

KOPECKY, Jindrich, Marek PASEK, Radek LAKOMÝ, Bohuslav MELICHAR, Ivona MRAZOVA et. al.

Basic information

Original name

The outcome in patients with BRAF-mutated metastatic melanoma treated with anti-programmed death receptor-1 monotherapy or targeted therapy in the real-world setting

Authors

KOPECKY, Jindrich (203 Czech Republic), Marek PASEK (203 Czech Republic), Radek LAKOMÝ (203 Czech Republic, belonging to the institution), Bohuslav MELICHAR (203 Czech Republic), Ivona MRAZOVA (203 Czech Republic), Ondrej KUBECEK (203 Czech Republic), Monika ARENBERGEROVA (203 Czech Republic), Radmila LEMSTROVA (203 Czech Republic), Alzbeta SVANCAROVA (203 Czech Republic), Vojtech TRETERA (203 Czech Republic), Alzbeta HLODAKOVA (203 Czech Republic) and Kamila ZVACKOVA (203 Czech Republic)

Edition

Cancer Medicine, HOBOKEN, WILEY, 2024, 2045-7634

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30204 Oncology

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 4.000 in 2022

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1002/cam4.6982

UT WoS

001185868200001

Keywords in English

BRAF mutation; immunotherapy; real-world data; targeted therapy

Abstract

V originále

Background: Immunotherapy and targeted therapy are currently two alternative backbones in the therapy of BRAF-mutated malignant melanoma. However, predictive biomarkers that would help with treatment selection are lacking. Methods: This retrospective study investigated outcomes of anti-programmed death receptor-1 monotherapy and targeted therapy in the first-line setting in patients with metastatic BRAF-mutated melanoma, focusing on clinical and laboratory parameters associated with treatment outcome. Results: Data from 174 patients were analysed. The median progression-free survival (PFS) was 17.0 months (95% CI; 8-39) and 12.5 months (95% CI; 9-14.2) for immunotherapy and targeted therapy, respectively. The 3-year PFS rate was 39% for immunotherapy and 25% for targeted therapy. The objective response rate was 72% and 51% for targeted therapy and immunotherapy. The median overall (OS) survival for immunotherapy has not been reached and was 23.6 months (95% CI; 16.1-38.2) for targeted therapy, with a 3-year survival rate of 63% and 40%, respectively. In a univariate analysis, age < 70 years, a higher number of metastatic sites, elevated serum LDH and a neutrophil-lymphocyte ratio above the cut-off value were associated with inferior PFS regardless of the therapy received, but only serum LDH level and the presence of lung metastases remained significant predictors of PFS in a multivariate analysis. Conclusions: Present real-world data document the high effectiveness of immunotherapy and targeted therapy. Although targeted therapy had higher response rates, immunotherapy improved PFS and OS. While the prognostic value of LDH was confirmed, the potential use of blood cell count-derived parameters to predict outcomes needs further investigation.

Citovat

KOPECKY, Jindrich, Marek PASEK, Radek LAKOMÝ, Bohuslav MELICHAR, Ivona MRAZOVA, Ondrej KUBECEK, Monika ARENBERGEROVA, Radmila LEMSTROVA, Alzbeta SVANCAROVA, Vojtech TRETERA, Alzbeta HLODAKOVA and Kamila ZVACKOVA. The outcome in patients with BRAF-mutated metastatic melanoma treated with anti-programmed death receptor-1 monotherapy or targeted therapy in the real-world setting. Cancer Medicine. HOBOKEN: WILEY, 2024, vol. 13, No 5, p. 1-17. ISSN 2045-7634. Available from: https://dx.doi.org/10.1002/cam4.6982.

@article{2417621,
   author = {Kopecky, Jindrich and Pasek, Marek and Lakomý, Radek and Melichar, Bohuslav and Mrazova, Ivona and Kubecek, Ondrej and Arenbergerova, Monika and Lemstrova, Radmila and Svancarova, Alzbeta and Tretera, Vojtech and Hlodakova, Alzbeta and Zvackova, Kamila},
   article_location = {HOBOKEN},
   article_number = {5},
   doi = {http://dx.doi.org/10.1002/cam4.6982},
   keywords = {BRAF mutation; immunotherapy; real-world data; targeted therapy},
   language = {eng},
   issn = {2045-7634},
   journal = {Cancer Medicine},
   title = {The outcome in patients with BRAF-mutated metastatic melanoma treated with anti-programmed death receptor-1 monotherapy or targeted therapy in the real-world setting},
   url = {https://onlinelibrary.wiley.com/doi/10.1002/cam4.6982},
   volume = {13},
   year = {2024}
}

TY  - JOUR
ID  - 2417621
AU  - Kopecky, Jindrich - Pasek, Marek - Lakomý, Radek - Melichar, Bohuslav - Mrazova, Ivona - Kubecek, Ondrej - Arenbergerova, Monika - Lemstrova, Radmila - Svancarova, Alzbeta - Tretera, Vojtech - Hlodakova, Alzbeta - Zvackova, Kamila
PY  - 2024
TI  - The outcome in patients with BRAF-mutated metastatic melanoma treated with anti-programmed death receptor-1 monotherapy or targeted therapy in the real-world setting
JF  - Cancer Medicine
VL  - 13
IS  - 5
SP  - 1-17
EP  - 1-17
PB  - WILEY
SN  - 20457634
KW  - BRAF mutation
KW  - immunotherapy
KW  - real-world data
KW  - targeted therapy
UR  - https://onlinelibrary.wiley.com/doi/10.1002/cam4.6982
N2  - Background: Immunotherapy and targeted therapy are currently two alternative backbones in the therapy of BRAF-mutated malignant melanoma. However, predictive biomarkers that would help with treatment selection are lacking. Methods: This retrospective study investigated outcomes of anti-programmed death receptor-1 monotherapy and targeted therapy in the first-line setting in patients with metastatic BRAF-mutated melanoma, focusing on clinical and laboratory parameters associated with treatment outcome. Results: Data from 174 patients were analysed. The median progression-free survival (PFS) was 17.0 months (95% CI; 8-39) and 12.5 months (95% CI; 9-14.2) for immunotherapy and targeted therapy, respectively. The 3-year PFS rate was 39% for immunotherapy and 25% for targeted therapy. The objective response rate was 72% and 51% for targeted therapy and immunotherapy. The median overall (OS) survival for immunotherapy has not been reached and was 23.6 months (95% CI; 16.1-38.2) for targeted therapy, with a 3-year survival rate of 63% and 40%, respectively. In a univariate analysis, age < 70 years, a higher number of metastatic sites, elevated serum LDH and a neutrophil-lymphocyte ratio above the cut-off value were associated with inferior PFS regardless of the therapy received, but only serum LDH level and the presence of lung metastases remained significant predictors of PFS in a multivariate analysis. Conclusions: Present real-world data document the high effectiveness of immunotherapy and targeted therapy. Although targeted therapy had higher response rates, immunotherapy improved PFS and OS. While the prognostic value of LDH was confirmed, the potential use of blood cell count-derived parameters to predict outcomes needs further investigation.
ER  -

KOPECKY, Jindrich, Marek PASEK, Radek LAKOMÝ, Bohuslav MELICHAR, Ivona MRAZOVA, Ondrej KUBECEK, Monika ARENBERGEROVA, Radmila LEMSTROVA, Alzbeta SVANCAROVA, Vojtech TRETERA, Alzbeta HLODAKOVA and Kamila ZVACKOVA. The outcome in patients with BRAF-mutated metastatic melanoma treated with anti-programmed death receptor-1 monotherapy or targeted therapy in the real-world setting. \textit{Cancer Medicine}. HOBOKEN: WILEY, 2024, vol.~13, No~5, p.~1-17. ISSN~2045-7634. Available from: https://dx.doi.org/10.1002/cam4.6982.

Detailed Information on Publication Record